Dr. Leal on the Rationale for the ECOG-ACRIN EA5161 Trial in ES-SCLC

Ticiana A. Leal, MD, medical oncologist, ​team leader, University of Wisconsin Carbone Cancer Center Thoracic Malignancies Disease Oriented Team, assistant professor, Division of Hematology, Medical Oncology and Palliative Care, University of Wisconsin ​School of Medicine and Public Health, discusses the rationale for the phase 2 ECOG-ACRIN EA5161 trial in extensive-stage small cell lung cancer (ES-SCLC). 

​Ultimately, the goal of the study was to improve therapy for patients with ES-SCLC, says Leal.

Notably, the randomized, cooperative group study began in 2017 when immunotherapy was added to platinum-based chemotherapy, in an attempt to boost tumor immunity.

This trial evaluate​d standard cisplatin/carboplatin and etoposide with or without the checkpoint inhibitor nivolumab (Opdivo) in the frontline setting for patients with ES-SCLC, Leal concludes.